Evaluation of risk factors for venous thromboembolism in Chinese women with epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 23, Issue 1, 2013, Pages 65-72

  Wu, Xiangxiang ^a   Xue, Xiang ^b   Tang, Jie ^a   Cheng, Xi ^a   Tian, Wenjuan ^a   Jiang, Rong ^a   Zang, Rongyu ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

D dimer; Hematologic index; High risk factors; Ovarian cancer; Venous thromboembolism

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; D DIMER; PROTHROMBIN;

ADULT; AGED; ARTICLE; ASCITES; BLOOD SAMPLING; CANCER PATIENT; CANCER SURGERY; CHINESE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; LEUKOCYTE COUNT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; OVARY TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; TUMOR VOLUME; UNIVERSITY HOSPITAL; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD CELL COUNT; CA-125 ANTIGEN; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84872301429     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318276dd87     Document Type: Article

References (25)

1. Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol. 2007;105:813-819.
2. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91:92-95.
3. Rodriguez AO, Wun T, Chew H, et al. Venous thromboembolism in ovarian cancer. Gynecol Oncol. 2007;105:784-790.
4. Satoh T, Oki A, Uno K, et al. High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer. 2007;97:1053-1057.
5. Uno K, Homma S, Satoh T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007;96:290-295.
6. Mereu L, Tateo S, Klersy C, et al. Stratification of venous thromboembolism risk in ovarian cancer patients during chemotherapy. Int J Gynecol Cancer. 2009;19:79-83.
7. Fotopoulou C, duBois A, Karavas AN, et al. Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum-/paclitaxel- containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. J Clin Oncol. 2008;26:2683-2689.
8. Tateo S, Mereu L, Salamano S, et al. Ovarian cancer and venous thromboembolic risk. Gynecol Oncol. 2005;99:119-125.
9. Suzuki N, Yoshioka N, Ohara T, et al. Risk factors for perioperative venous thromboembolism: a retrospective study in Japanese women with gynecologic diseases. Thromb J. 2010;8:17.
10. Abu-Rustum NR, Richard S, Wilton A, et al. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol Oncol. 2005;99:320-326.
11. Adam SS, Key NS, Greenberg CS. D-dimer antigen: current concepts and future prospects. Blood. 2009;113:2878-2887.
12. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol. 2000;18:600-608.
13. Gadducci A, Baicchi U, Marrai R, et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol. 1996;60:197-202.
14. Kodama J, Seki N, Masahiro S, et al. D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer. Ann Oncol. 2010;21: 1651-1656.
15. Acosta S, Alhadad A, Svensson P, et al. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg. 2008;95:1245-1251.
16. Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis. Crit Rev Oncol Hematol. 2007;62:126-136.
17. Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104:2822-2829.
18. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-4907.
19. Trujillo-Santos J, Di Micco P, Iannuzzo M, et al. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:905-911.
20. Tefferi A, Gangat N, Wolanskyj A. The interaction between leukocytosis and other risk factors for thrombosis in essential thrombocythemia. Blood. 2007;109:4105.
21. Satoh T, Matsumoto K, Uno K, et al. Silent venous thromboembolism before treatment in endometrial cancer and the risk factors. Br J Cancer. 2008;99:1034-1039.
22. Kirwan CC, McDowell G, McCollum CN, et al. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer. 2008;99:1000-1006.
23. Gadducci A, Marrai R, Baicchi U, et al. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer. Anticancer Res. 1995;15:2683-2686.
24. Maksimovic M, Gojnic M, Maksimovic Z, et al. Surgical treatment of ovarian cancer and early detection of venous thromboembolism. Eur J Gynaecol Oncol. 2011;32:415-418.
25. Fotopoulou C, Karavas A, Trappe R, et al. Venous thromboembolism in recurrent ovarian cancer-patients: a systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO). Thromb Res. 2009;124:531-535.